MOv19-BBz CAR T Cells in FRa+ Cancers
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana świadoma zgoda na udział w badaniu
- •Nowotwór musi mieć specjalny marker (FRa) potwierdzony badaniem tkanki
- •Zaawansowany lub nawrotowy rak płuca z płynem w opłucnej
- •Wcześniejsze leczenie co najmniej jednym standardowym lekiem
- •Aktywna choroba potwierdzona badaniami obrazowymi
- •Prawidłowa funkcja nerek, wątroby i serca
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny (możliwość wykonywania codziennych czynności)
✗ Disqualifies
- •Płyn w opłucnej, którego nie można odpompować standardowymi metodami
- •Poważne choroby płuc lub rozległy nowotwór w płucach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Pennsylvania
Philadelphia, United States
Trial contact
Abramson Cancer Center Clinical Trials Service
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.